By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – BioTime today announced that its majority-owned subsidiary OncoCyte has received $10 million in a new round of equity financing, which it will use to further develop diagnostics and therapeutics for cancer.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In PLOS this week: genes under positive selection in Plasmodium falciparum populations, genetic variation in Epstein-Barr viruses, and more.

Cancer clinical trial patients settle with Anil Potti and Duke University.

A trio of researchers is trying to raise money to sequence and analyze the genome of a cat with a suite of unusual traits.

Two Johns Hopkins researchers discuss the need for evidence-based data analysis.